Persons with co-existing neurological disorders: Risk analysis, considerations and management in COVID-19 pandemic

2021 ◽  
Vol 20 ◽  
Author(s):  
Sumit Sharma ◽  
Sonali Batra ◽  
Saurabh Gupta ◽  
Vivek Kumar Sharma ◽  
Md Habibur Rahman ◽  
...  
Keyword(s):  
Risk Analysis ◽  
Respiratory Tract ◽  
Cohort Studies ◽  
Cerebrovascular Disease ◽  
Neurological Disorders ◽  
Management Strategy ◽  
Clinical Manifestations ◽  
Neurological Symptoms ◽  
Neurological Manifestations ◽  
Standardized Diagnostic

: Increasing reports of neurological symptoms in COVID-19 patient’s warrant clinicians to adopt and define the standardized diagnostic and managing protocols in order to investigate the linkage of neurological symptoms in COVID-19. Encephalitis, anosmia, acute cerebrovascular disease and ageusia are some of the emerging neurological manifestations which are reported in several cohort studies on hospitalized patients with COVID-19. Although the COVID-19 pandemic is primarily associated with respiratory tract system but measures like lockdown and restricted physical movements to control the spread of this infection will certainly have neurobehavioural implications. Additionally, some of the patients with pre-existing neurological manifestations like epilepsy, Parkinson’s and Alzheimer’s disease are more prone to infection and demands extra as well as improvisation in their treatment therapy. In this review we have focused on the neurovirological clinical manifestations associated with COVID-19 pandemic. Although the prevalence of neurovirological manifestations is rare but increasing reports cannot be ignored and needs to be discussed thoroughly with respect to risk analysis and considerations for developing management strategy. This also helps in defining the burden of neurological disorders associated with COVID-19 patients.

scholarly journals Neurological manifestations of COVID-19 – an approach to categories of pathology

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Yana Leven ◽  
Julian Bösel
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Cerebrovascular Disease ◽  
Literature Search ◽  
Case Series ◽  
Neurological Symptoms ◽  
Comparable Data ◽  
Neurological Manifestations ◽  
Case Definitions ◽  
The Central Nervous System

Abstract Background Various neurological manifestations of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported, associated with a broad spectrum of diverse neurological symptoms and syndromes. Estimating rate and relevance of these manifestations remains difficult as there is a lack of standardised case definitions. Methods We defined comprehensive categories including most reported neurological manifestations associated with SARS-CoV-2 to allow for a more standardised data collection. After a literature search of MEDLINE with ten keywords, 12 selected studies and larger case series were included. We compared the rate and relevance of neurological manifestations in hospitalized patients. We propose four main categories including 1) cerebrovascular disease, 2) inflammatory syndromes of the central nervous system (CNS), peripheral nervous system (PNS) and muscle, 3) metabolic/toxic dysfunction of CNS, PNS and muscle and 4) miscellaneous disorders. Conclusion Ageusia (702) and anosmia (805) have been reported as the most common and the first occurring neurological symptoms. Cerebrovascular disease (451) and encephalopathy (663) were associated with a more severe course and worse clinical outcome. Any neurological manifestation was associated with a longer hospital stay and a higher morbidity and mortality compared to patients without neurological manifestations. We suggest reporting future neurological manifestations of coronavirus disease-19 (COVID-19) following a pathophysiology-based approach using standardized pre-defined case definitions to yield more specific and comparable data.

scholarly journals Ischaemic stroke as an initial presentation in patients with COVID-19: evaluation of a case series in an emergency in Brazil

2021 ◽  
pp. 197140092098735
Author(s):  
Isabella B Oliveira ◽  
Mariana SL Pessoa ◽  
Carla FC Lima ◽  
Jorge LB Holanda ◽  
Pablo P de A Coimbra
Keyword(s):  
Respiratory Tract ◽  
Ischaemic Stroke ◽  
Laboratory Tests ◽  
Case Series ◽  
Neurological Symptoms ◽  
Initial Presentation ◽  
Cytokine Storm ◽  
Neurological Manifestations ◽  
Global Impact

The disease caused by the new coronavirus, initially described in China in December 2019, became known as coronavirus disease 2019 and quickly spread to countries on all continents, becoming a pandemic with an important global impact. Despite being a virus that typically affects the respiratory tract, some studies have already described neurological manifestations associated with this infection, including acute ischaemic vascular insult. We report a case series including 30 patients, who presented with neurological symptoms during admission to our service, being diagnosed with ischaemic stroke and, concomitantly, coronavirus disease 2019. In the subgroup of patients analysed, a state of hypercoagulability and pro thrombosis was observed through laboratory tests, probably related to the cytokine storm syndrome associated with infection by this virus. With that, we discussed the possibility of this finding being an aggravating factor in the occurrence of stroke in these patients.

scholarly journals Neurological Manifestations in COVID-19 Population: A Short Review

2021 ◽  
pp. 097275312199024
Author(s):  
Kamal Pratap Singh ◽  
Rachna Agarwal
Keyword(s):  
Mental Health ◽  
Cohort Studies ◽  
Case Reports ◽  
Large Population ◽  
Short Review ◽  
Individual Case ◽  
Neurological Symptoms ◽  
The Novel ◽  
Neurological Manifestations ◽  
Research Papers

Background: Coronaviruses (CoVs) have a neuroinvasive potential, which has been discussed in various research papers. During the current pandemic, the novel CoV, i.e., SARS-CoV-2, is causing a considerable number of fatalities and posing a great danger of a recurrent epidemic. COVID-19 has been labeled as a public health emergency of international concern, and the epidemic curves are on the rise. Purpose: Some studies discuss the neurological implications of SARS-CoV-2 but in light of growing number of evidences we cannot ignore the planning of mental health care settings in COVID-19. We are discussing how this novel CoV can affect the human brain directly and indirectly, including psychiatric problems, and how neurological conditions can be explored as a diagnostic tool in COVID-19 by analyzing cohort studies and review papers that discuss the recent neurological findings in COVID-19. Method: Current research and review papers were searched to find out any relation between the COVID-19 disease and the altered mental health. This study attempts to find out neurological symptoms in a large population affected by COVID-19 and thus filtering out individual case reports and cohort studies which have a patient pool of less than 50. Results: This unique observation revealed that SARS-CoV-2 has direct neurological manifestations such as anosmia and gustatory impairment, encephalopathy, and seizures as well as an indirect effect on the psychiatric health such as anxiety, amnesia, etc. because of psychosocial stress. Conclusion: The most commonly reported neurological symptoms should not be ignored and must be tested for COVID-19. More neurological studies like medical imaging and neuropathology should be performed on these COVID-19 patients.

Respiratory tract damage with bocavirus infection in children

2020 ◽  
Vol 19 (2) ◽  
pp. 14-18
Author(s):  
E. V. Sharipova ◽  
I. V. Babachenko ◽  
M. A. Shcherbatyh
Keyword(s):  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Clinical Manifestations ◽  
Respiratory Viruses ◽  
Community Acquired Pneumonia ◽  
Human Bocavirus ◽  
Long Time ◽  
Clinically Significant ◽  
Tract Infections ◽  
Tract Damage

Long time the main pathogens associated with the development of community-acquired pneumonia were bacteria. However, in recent years in the Russian Federation, like all over the world, the view of the damage of lower respiratory tract changed, including a unique approach to community-acquired pneumonia as a bacterial infection, and respiratory viruses have become seen as a direct cause of lower respiratory tract damage, or as part of a viral-bacterial co-infection. These studies became possible since the widespread introduction of PCR techniques in the clinical setting, identification of respiratory viruses has increased and new microorganisms such, one as human bocavirus have been discovered. Objective: to study the features of respiratory tract damage in acute bocavirus infection in children of different ages. Materials and methods: A retrospective analysis of 97 medical hospital documentation of children with acute bocavirus infection, detected confirmed by PCR in nasopharyngeal aspirate. Results: In this work, it was shown that human bocavirus spread throughout the year with an increase in the incidence of clinically significant forms in the autumnwinter period, including during the period of an increase in the incidence of influenza. HBoV infection requiring hospitals is most significant in the first three years of life. In 74.2% of hospitalized children, bocavirus infection occurs with lower respiratory tract infections in the form of bronchitis — 77.8%, pneumonia — 28.9% and rarely bronchiolitis and is complicated by the development of respiratory failure in 28.9% of cases. Changes in the blood test are non-specific, and the level of C-reactive protein in children with various clinical manifestations of HBoV infection generally does not exceed 50 mg / l. An x-ray of the chest organs does not objectively reflect the existing volume and nature of the inflammatory process in the lungs.

scholarly journals Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)

2021 ◽  
Author(s):  
Biyan Nathanael Harapan ◽  
Hyeon Joo Yoo
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Case Reports ◽  
Case Series ◽  
Altered Mental Status ◽  
Neurological Complications ◽  
Neurological Symptoms ◽  
Neurological Manifestations ◽  
Fisher Syndrome ◽  
Novel Coronavirus ◽  
The Impact

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is responsible for the outbreak of coronavirus disease 19 (COVID-19) and was first identified in Wuhan, China in December 2019. It is evident that the COVID-19 pandemic has become a challenging world issue. Although most COVID-19 patients primarily develop respiratory symptoms, an increasing number of neurological symptoms and manifestations associated with COVID-19 have been observed. In this narrative review, we elaborate on proposed neurotropic mechanisms and various neurological symptoms, manifestations, and complications of COVID-19 reported in the present literature. For this purpose, a review of all current published literature (studies, case reports, case series, reviews, editorials, and other articles) was conducted and neurological sequelae of COVID-19 were summarized. Essential and common neurological symptoms including gustatory and olfactory dysfunctions, myalgia, headache, altered mental status, confusion, delirium, and dizziness are presented separately in sections. Moreover, neurological manifestations and complications that are of great concern such as stroke, cerebral (sinus) venous thrombosis, seizures, meningoencephalitis, Guillain–Barré syndrome, Miller Fisher syndrome, acute myelitis, and posterior reversible encephalopathy syndrome (PRES) are also addressed systematically. Future studies that examine the impact of neurological symptoms and manifestations on the course of the disease are needed to further clarify and assess the link between neurological complications and the clinical outcome of patients with COVID-19. To limit long-term consequences, it is crucial that healthcare professionals can early detect possible neurological symptoms and are well versed in the increasingly common neurological manifestations and complications of COVID-19.

Morphologic changes and prognosis of the respiratory tract epithelium in inhalation injury and their relationship with clinical manifestations

Surgery ◽  
2012 ◽  
Vol 151 (2) ◽  
pp. 206-212 ◽  
Author(s):  
Li Ligen ◽  
Yang Hongming ◽  
Li Feng ◽  
Shen Chuanan ◽  
Hao Daifeng ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Clinical Manifestations ◽  
Inhalation Injury ◽  
Morphologic Changes

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies

Lupus ◽  
2018 ◽  
Vol 27 (8) ◽  
pp. 1296-1302 ◽  
Author(s):  
J Tanwani ◽  
K Tselios ◽  
D D Gladman ◽  
J Su ◽  
M B Urowitz
Keyword(s):  
Comparative Analysis ◽  
Cohort Studies ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Data Retrieval ◽  
Complete Recovery ◽  
University Of Toronto ◽  
Single Center Experience ◽  
Organ Systems ◽  
Lupus Myocarditis

Background Lupus myocarditis (LM) is reported in 3–9% of patients with systemic lupus erythematosus (SLE) but limited evidence exists regarding optimal treatment and prognosis. This study aims to describe LM in a defined lupus cohort as compared with the existing literature. Patients and methods Patients with LM were identified from the University of Toronto Lupus Clinic database. Diagnosis was based on clinical manifestations and electrocardiographic, imaging, and biochemical criteria. Demographic, clinical, diagnostic and therapeutic variables and outcomes were collected in a standardized data retrieval form. A literature review was performed to identify cohort studies reporting on LM treatment and outcome. A comparative analysis was conducted between our patients and the combined cohort of the existing studies. Results Thirty patients were diagnosed with LM (prevalence 1.6%) and compared with a cumulative cohort of 117 patients from five distinct studies. No significant differences were found regarding the age at diagnosis (32.6 ± 13.4 years) and SLE duration (2.5 years median). Concomitant lupus activity from other organ systems was observed in 97% of the patients. Chest pain was more frequently reported in our cohort whereas dyspnea was more prominent in the other studies. Diagnostic criteria were similar across studies. Therapeutic approach was comparable and consisted of glucocorticosteroids (96.6%) and immunosuppressives (70%). Mortality was approximately 20% whereas another 20% of the patients achieved partial and 60% complete recovery. Conclusions LM usually occurs early in the disease course and in the context of generalized lupus activity. Despite aggressive therapy, approximately 40% of the patients died or had residual heart damage.

HEREDITARY ANGIOEDEMA – A PROBLEM AT THE INTERSECTION OF IMMUNOLOGY AND ALLERGOLOGY: ANALYSIS OF LITERATURE DATA AND DESCRIPTION OF A SERIES OF 34 CASES

2021 ◽  
Vol 100 (2) ◽  
pp. 49-57
Author(s):  
M.N. Guseva ◽  
◽  
E.I. Zinina ◽  
E.N. Suspitsyn ◽  
M.M. Kostik ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Hereditary Angioedema ◽  
Positive Family History ◽  
Clinical Manifestations ◽  
Upper Respiratory Tract ◽  
Upper Airways ◽  
Peripheral Edema ◽  
Dominant Disease ◽  
Characteristic Features ◽  
Head Neck

Hereditary angioedema (HAE) is a rare autosomal dominant disease characterized by isolated recurrent angioedema (AE) of various localizations: skin, the submucosa in the gastrointestinale tract, the respiratory tract. The characteristic features of edema in HAE are the absence of itching, skin flushing, accompanying urticaria, as well as the absence of pronounced effect of systemic corticosteroid therapy, systemic antihistamines therapy and adrenaline. The aim of our study was to present a descriptive characteristics of the group of patients with HAE and to access efficacy and safety of treatment. Materials and methods: the retrospective multicenter continuous nonrandomized uncontrolled study included data on 34 patients: 19 men (56%) and 15 women (44%) with HAE. The diagnosis of HAE was based on clinical and laboratorial data, according to the clinical guidelines of the Russian Association of allergologists and clinical immunologists on HAE (2014). Results The age range of patients at the time of inclusion in the study was 5–82 years, median – 38,8 (20,6; 46,9) years. Median age of first HAE episode was 12,5 (5,8; 16,3) years, ranged from 2 to 40, 22/28 (79%) of the patients manifested before 18 years. HAE was diagnosed at the median age of 30 years (17,5; 44,8) years, in 14,0 (9,0; 25,0) years after onset of the clinical manifestations. Most of the observations described have a positive family history of HAE (91%), in total 9 families were described. In 67% of families the disease manifested itself in two generations and in 33% of families – in three generations. At the onset of HAE peripheral edema was in 29/31 (94%) of the patients, and 22/31 (71%) had edema confined to the distal extremities. 7/31 (29%) patients had peripheral edema combined with edema of other locations. Abdominal attacks were in 6/31 (19%), head, neck and upper airways edema were in 7/31 (23%). The frequency of swelling of head, neck, upper respiratory tract increased statistically significantly from 23% (7/31) to 35% (7/20, p=0,003). 24 patients have recieved Icatibant treatment. No deaths were recorded against the background of this treatment. Conclusions HAE is diagnosed with significant time delays. Icatibant treatment is safe and effective.

Sign in / Sign up

Export Citation Format

Share Document